To address these challenges, we conducted a retrospective clinical analysis combined with in vitro cellular studies to explore the real-world clinical efficacy of neoadjuvant combination therapy based on HLX02 in patients with HER2-positive early-stage BC, with a particular focus on the HR-positive subgroup. Here, ERBB2 is linked to breast cancer.